Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis

Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis

Abstract Dipeptidyl-peptidase-4 inhibitors (DPP4i) have been the most used antidiabetic medications worldwide due to their good safety profiles and tolerability with a low risk of hypoglycemia, however, large cardiovascular outcome trials (CVOTs) have not shown any significant the prognostic superio...

Full description

Bibliographic Details
Main Authors: Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, Takuma Koike, Hidetoshi Yasuda, Takehiro Funamizu, Shinichiro Doi, Hirohisa Endo, Hideki Wada, Ryo Naito, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Kikuo Isoda, Shinya Okazaki, Katsumi Miyauchi, Tohru Minamino
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-09059-2

Internet

https://doi.org/10.1038/s41598-022-09059-2

Similar Items